Hansa Biopharma develops enzyme-based therapies that cleave IgG antibodies, targeting rare autoimmune and transplant-related conditions. Its lead product, imlifidase (Idefirix), is used to desensitize highly sensitized patients so they can receive kidney transplants when standard cross-matching would otherwise block surgery. The company focuses on specialty immunology indications where rapid removal of pathogenic IgG can change clinical outcomes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 66.3 | — | -38.9 | — |
| Q2 2025 | 49.1 | — | -197 | — |
| Q4 2025 | 76 | — | -165 | — |
| Q1 2026 | 34.6 | -47.9% | -196.3 | — |
| Q2 2026 | 48.1 | -2.1% | -260.5 | — |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Kambi Group plc (KAMBI), Eastnine AB (publ) (EAST), Ovzon AB (publ) (OVZON), John Mattson Fastighetsföretagen AB (publ) (JOMA), FM Mattsson AB (publ) (FMM B), Prisma Properties AB (publ) (PRISMA)